ALS Clinical Trials
Here are the 6 most popular medical studies for als
Brain Computer Interface
BCI-FIT for Parkinson's Disease
This trial is testing a new brain-computer interface (BCI) that does not require surgery for people with severe speech and physical impairments. The goal is to improve communication for people with these impairments.
Popular filter options for als trials
ALS Clinical Trials
View 64 ALS medical studies.
Procedure
Mechanical Insufflation for Amyotrophic Lateral Sclerosis
This trial will study how using a device to mechanically insufflate & exsufflate affects breathing in early ALS. It will compare results of 20 patients using the device to 20 who don't.
Rehabilitation for Amyotrophic Lateral Sclerosis
This trial studies the effects of personalized rehabilitation programs on people with SOD1 ALS who are receiving treatment with tofersen. They will get assessments and individualized therapy. Assessments will happen every 3 months.
Lou Gehrig's Disease Clinical Trials
View 13 Lou Gehrig's Disease medical studies.
Antipsychotic
Pimozide for Amyotrophic Lateral Sclerosis
This study will look at whether Pimozide may help to slow the progression of Amyotrophic Lateral Sclerosis. 100 people from several Canadian centres with ALS who have provided their consent will be randomly assigned into one of 2 groups. The first group will receive a dose of up to 2mg of Pimozide per day and the second group will receive placebo (lactose tablets). Subjects will be assigned randomly (like by a flip of a coin) to receive either Pimozide 2 mg per day or placebo tablets. There will be a fifty-fifty chance of receiving Pimozide or placebo. Participants will be on study medication up to 22 weeks, and on study up to 26 weeks. There are 8 clinic visits and 1 phone visit over the course of the Treatment Phase of the study. The second phase which is Observational, is optional with follow-up for up to 5 years from the end of the Treatment Phase.
Mesenchymal Stem Cells
Autologous Adipose-derived Mesenchymal Stromal Cells for Lou Gehrig's Disease
This trial will test the safety and efficacy of delivering MSCs to the CSF of people with ALS every 3 months for a total of 4 injections over 12 months. The goal of the study is to determine if this treatment is safe and can improve the subject's ALS symptoms.
Phase 3 Amyotrophic Lateral Sclerosis Clinical Trials
View 67 phase 3 amyotrophic lateral sclerosis medical studies.
Investigational Treatments for Amyotrophic Lateral Sclerosis in the HEALEY ALS Platform Trial
This trial is for people with ALS who are looking for new treatment options. It is a perpetual trial, which means it is ongoing, and testing multiple products for safety and efficacy.
Amyotrophic Lateral Sclerosis Clinical Trials With No Placebo
View 67 amyotrophic lateral sclerosis medical studies that do not have a placebo group.
Procedure
Mechanical Insufflation for Amyotrophic Lateral Sclerosis
This trial will study how using a device to mechanically insufflate & exsufflate affects breathing in early ALS. It will compare results of 20 patients using the device to 20 who don't.
Rehabilitation for Amyotrophic Lateral Sclerosis
This trial studies the effects of personalized rehabilitation programs on people with SOD1 ALS who are receiving treatment with tofersen. They will get assessments and individualized therapy. Assessments will happen every 3 months.
View More Als Trials
See another 38 many medical studies focused on als.
Frequently Asked Questions
Introduction to als
What are the top hospitals conducting als research?
When it comes to advancing the understanding and treatment of amyotrophic lateral sclerosis (ALS), several hospitals have emerged as pioneers in clinical trials. Massachusetts General Hospital, located in the vibrant city of Boston, is at the forefront with an impressive ten ongoing ALS trials and a remarkable history of 62 completed studies dedicated to this challenging condition. Since conducting their first trial in 2001, they have been relentless in their pursuit to find effective treatments.
In Toronto, Sunnybrook Health Sciences Centre has become a beacon of hope for individuals living with ALS. With five active clinical trials underway and thirteen previously conducted studies since their inaugural trial in 2014, they are making significant strides towards unraveling the mysteries surrounding this devastating disease.
Down south in Jacksonville, Floridais (ALS), several hospitals have emerged as pioneers in clinical trials. Massachusetts General Hospital, located in the vibrant city of Boston, is at the forefront with an impressive ten ongoing ALS trials and a remarkable history of 62 completed studies dedicated to this challenging condition. Since conducting their first trial in 2001, they have been relentless in their pursuit to find effective treatments.
In Toronto, Sunnybrook Health Sciences Centre has become a beacon of hope for individuals living with ALS. With five active clinical trials underway and thirteen previously conducted studies since their inaugural trial in 2014, they are making significant strides towards unraveling the mysteries surrounding this devastating disease.
Down south in Jacksonville, Florida's Mayo Clinic is also lending its expertise to fight against ALS. They currently have five active clinical trials and a total of fifteen past endeavors under their belt since embarking on their first study in 2003. Their dedication extends beyond geographical boundaries as they contribute valuable knowledge to the global community.
Similarly invested is Emory University situated amidst Atlanta's bustling medical landscape. Alongside offering top-notch care for patients with ALS, Emory University actively engages in five ongoing clinical trials while having accomplished nineteen previous investigations since recording its initial trial back in 2003.
Meanwhile Augusta University boasts a more recent contribution but one that should not be underestimated; starting from just four existing current experiments until now gradually accumulating eight researches over time ever since taking up its maiden endeavor only six years ago back around2016
These institutions represent beacons of hope for those affected by ALS worldwide – each bringing unique perspectives and expertise to unravel this complex condition further. By dedicating themselves wholeheartedly to these critical research efforts, these hospitals pave the way towards finding better treatments and ultimately enhancing the lives of countless individuals impacted by ALS
Which are the best cities for als clinical trials?
When it comes to ALS clinical trials, several cities stand out as hubs for research and development. Boston, Massachusetts leads the way with 21 active trials investigating promising treatments like BIIB105, Pridopidine, and Baricitinib. New York City follows closely behind with 16 ongoing studies focused on SAR443820, Part D: Open-Label Treatment, dalfampridine, and other potential therapies. Baltimore, Maryland also emerges as a significant player in ALS research with 15 active trials exploring treatments such as BIIB105 and Pegcetacoplan (APL-2). Together with Toronto's 14 active trials studying various interventions including Part D: Open-Label Treatment and San Francisco's investigations into PTC857, Pridopidine, and ANX005; these cities offer individuals affected by ALS access to cutting-edge clinical trials that hold promise for advancing treatment options.
Which are the top treatments for als being explored in clinical trials?
Exciting advancements are taking place in ALS research, with several top treatments being explored in clinical trials. DNL343 is currently leading the pack with two active trials dedicated to ALS. This promising treatment made its debut in 2020 and has already gained recognition for its potential. Another contender, PTC857, is making waves with one ongoing trial focused on ALS after being first listed just this year (2022). Additionally, AP-101 shows promise as it undergoes an active trial for ALS treatment. Since its introduction in 2019, it has been involved in a total of two clinical trials dedicated to combating this debilitating disease. These innovative therapies offer hope to those affected by ALS and bring us closer to finding effective solutions for this challenging condition.
What are the most recent clinical trials for als?
Exciting developments are underway in the field of amyotrophic lateral sclerosis (ALS) research, with recent clinical trials offering promising prospects for patients. One notable trial is evaluating the potential of DNL343 to treat ALS, with both Phase 2 and Phase 3 studies currently underway since May 24, 2023. Another study worth mentioning is investigating CK0803 as a treatment option for ALS patients, following its availability in April 2023 during Phase 1 trials. Additionally, ABBV-CLS-7262 has shown promise in treating ALS and is progressing through Phase 2 and Phase 3 studies since March 23, 2023. This evolving landscape offers renewed hope to individuals affected by ALS as researchers strive towards finding effective treatments for this debilitating condition.
What als clinical trials were recently completed?
In the realm of ALS clinical trials, several noteworthy studies have recently achieved completion, bringing hope to those affected by this challenging condition. Merit E. Cudkowicz, MD spearheaded a trial investigating Pridopidine that concluded in December 2020. Another promising therapy, AMX0035, underwent testing sponsored by Amylyx Pharmaceuticals Inc., with results becoming available in November 2020. Moreover, Richard Bedlack, M.D., Ph.D., successfully completed a trial exploring Theracurmin HP in August 2020. Notably as well, Merit E. Cudkowicz was involved in multiple investigations that culminated around July 2020: CNM-Au8 study for potential treatment and Zilucoplan and Verdiperstat trials showcasing innovative approaches towards combating ALS symptoms. These significant advancements reflect the tireless efforts of researchers striving to conquer ALS and enhance patient outcomes.